TheraVet Announces the Start of the Assessment of BIOCERA-VET® in Horse Bone Cyst
16 February 2023 - 3:45AM
Business Wire
Regulatory News:
TheraVet (ISIN: BE0974387194 - ticker: ALVET) (Paris:ALVET)
(Brussels:ALVET), a pioneering company in the management of
osteoarticular diseases in pets, is delighted to announce its
collaboration with Dr Ter Braake, a European Specialist in Equine
Surgery (Dierenkliniek Emmeloord, The Netherlands) in the
evaluation of BIOCERA-VET® Ready-To-Use as a new treatment option
for horse bone cysts.
Bone cysts are abnormalities of bones and joints that can occur
in multiple sites in horses. Bone cysts are frequent with a
prevalence of 25% in yearlings (racehorses in their second year).
Common cause of horse lameness, especially in the young equine
athlete, is subchondral cyst lesions (SCL). During pre-purchasing
examinations, early stage SCL can be found in apparently sound
horses as well, representing a concern to many horse owners.
So far, non-surgical and surgical management of bone cysts are
not fully satisfactory in returning the horses to full soundness
and therefore, vets are looking for new arthroscopic/mini-invasive
approaches including bone grafts.
BIOCERA-VET® Ready-To-Use, an injectable bone graft, is a
promising product to be used in such surgical approach. Indeed,
thanks to its unique properties, it can be easily injected by
minimally invasive procedure (such as arthroscopy), promoting a
faster recovery. Also, BIOCERA-VET®, due to its composition close
to the natural composition of the bone, stimulates bone growth and
is gradually replaced with new bone tissue leading in the
resolution of the bone cyst and ultimately its clinical
consequences.
Thanks to our collaboration with Dr Ter Braake, a first case of
bone cyst has been successfully treated.
Dr. Ter Braake, DVM, CERT EP, EBVS, EVCS comments: “My initial
evaluation of filling a subchondral cyst lesion with BIOCERA-VET®
in a young horse showed promising results. A complete filling of
the cavity was achieved, with consistent new bone formation and no
lameness. I’m looking forward to continue my collaboration with
TheraVet and use this technology on more cases presented in my
equine clinic.”
About TheraVet SA
TheraVet is a veterinary biotechnology company specialising in
osteoarticular treatments for companion animals. The Company
develops targeted, safe and effective treatments to improve the
quality of life of pets suffering from joint and bone diseases. For
pet owners, the health of their pets is a major concern and
TheraVet’s mission is to address the need for innovative and
curative treatments. TheraVet works closely with international
opinion leaders in order to provide a more effective response to
ever-growing needs in the field of veterinary medicine. TheraVet is
listed on Euronext Growth® Paris and Brussels, has its head office
in Belgium (Gosselies) with a US subsidiary in Texas.
For more information, visit the TheraVet website or follow us on
LinkedIn / Facebook / Twitter
About BIOCERA-VET
In close collaboration with an international scientific board,
THERAVET® has developed a new line of calcium-phosphate and
biological bone substitutes, BIOCERA-VET®. BIOCERA-VET® is a full
range of innovative, easy-to-use, efficient & cost-effective
bone substitutes indicated in bone surgeries where a bone graft is
required and as a palliative alternative in the management of
canine osteosarcoma. Based on extremely promising clinical results,
this line offers the possibility of a better, more convenient and
more efficient orthopedic surgery.
BIOCERA-VET® is declined in different lines:
- BIOCERA-VET® BONE SURGERY RTU, ready-to-use highly injectable
self-hardening calcium-phosphate cement
- BIOCERA-VET® SMARTGRAFT, a naturally osteoconductive bone
graft
- BIOCERA-VET® GRANULES, an affordable biocompatible
calcium-phosphate bone substitute
- BIOCERA-VET® OSTEOSARCOMA RTU, a ready-to-use highly injectable
calcium-phosphate bone substitute for cementoplasty
For more information, visit BIOCERA-VET website.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230215005619/en/
TheraVet Chief Operating Officer Sabrina Ena
investors@thera.vet Tel: +32 (0) 71 96 00 43
Chief Corporate Officer Julie Winand
investors@thera.vet
NewCap Investor Relations and Financial Communications
Théo Martin/Nicolas Fossiez theravet@newcap.eu Tel: +33 (0)1 44 71
94 94
Press Relations Arthur Rouillé theravet@newcap.eu Tel: +33 (0)1
44 71 00 15
NewCap Belgique Press Relations Laure-Eve Monfort
lemonfort@newcap.fr Tel: + 32 (0) 489 57 76 52
TheraVet (EU:ALVET)
Historical Stock Chart
From Mar 2024 to Apr 2024
TheraVet (EU:ALVET)
Historical Stock Chart
From Apr 2023 to Apr 2024